Eledon Pharmaceuticals, Inc. (ELDN) Stock

Eledon Pharmaceuticals, Inc. (ELDN) is a Healthcare stock trading at $3.91 (as of 2026-06-18), with a market capitalization of $294.09M and a trailing P/E of -4.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for people with autoimmune disorders and amyotrophic lateral sclerosis (ALS), including settings requiring an organ or cell-based transplant. Its lead candidate, AT-1501, is a humanized monoclonal antibody targeting CD40 ligand, studied in ALS and in islet cell transplantation for type 1 diabetes.

Valuation — source: SEC EDGAR (first-party)
Price	$3.91
Market Cap	$294.09M
P/E Ratio	-4.6
Price / Book	6.16
DCF Value (model)	$-13.69
DCF Upside vs Price	-450.1%

Profitability & Growth — source: SEC EDGAR
Return on Equity	-174.6%
Current Ratio	8.44

Valuation vs Sector & Industry
Stock P/E	-4.6
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-122.2%
vs Industry	-127.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BVF INC/IL ($19.38M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	David-Alexandre C. Gros
Employees	31
Country	US
IPO Date	2014-09-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.